艾乐明®(巴瑞替尼片)
本页包括过去3年在同行评审期刊上发表的礼来发起的临床试验。
以下列表仅限于与已批准使用的产品相关的出版物,
可能是非适应症的。(请参见产品完整处方信息链接)
如果您对下面未列出的礼来研究有任何疑问,或希望获得本页期刊出版物的电子版,
请联系下面的礼来客户服务中心以获得进一步的帮助。
活动性类风湿关节炎患者在巴瑞替尼临床试验中的感染
Infections in Baricitinib Clinical Trials for Patients with Active Rheumatoid Arthritis
发表日期:2020-08-11
从中度至重度成人特应性皮炎患者的血液循环生物标志物数据中分析其异质性
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease
发表日期:2021-07-06
在一项为期24周的Ⅱ期系统性红斑狼疮临床试验中,巴瑞替尼相关的整体基因表达变化提示其通过多种免疫相关途径的作用机制
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
发表日期:2020-10-09
活动性类风湿关节炎患者在巴瑞替尼临床试验中的感染
Infections in Baricitinib Clinical Trials for Patients with Active Rheumatoid Arthritis
发表日期:2020-08-11
巴瑞替尼的机制支持在COVID-19患者中进行人工智能预测测试
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients
发表日期:2020-06-24
在长期扩展研究 BREEZE-AD3 的随机子研究中,巴瑞替尼成功治疗中重度特应性皮炎患者后,与连续给药相比的减量或停药的疗效
Efficacy of downtitration or treatment withdrawal compared to continuous dosing, after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomised substudy from the long-term extension study, BREEZE-AD3
发表日期:2022-11-17
特应性皮炎经验证的研究者整体评估(vIGA-AD™):针对特应性皮炎严重程度的临床结局检测方法
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): A Clinical Outcome Measure for the Severity of Atopic Dermatitis
发表日期:2022-04-20
在美国临床试验 (BREEZE-AD5) 中使用巴瑞替尼治疗的特应性皮炎患者的日常日记中报告的症状缓解起效时间
Onset of Symptom Relief Reported in Daily Diaries in Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)
发表日期:2022-01-28
在巴瑞替尼 3 期试验中,瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的贡献。
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
发表日期:2022-01-18
使用阿片类药物的类风湿关节炎患者的疼痛减轻:巴瑞替尼 3 期试验的事后分析
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
发表日期:2021-12-16
巴瑞替尼治疗COVID-19住院成人的有效性与安全性(COV-BARRIER):一项随机、双盲、平行组、安慰剂对照3期试验
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
发表日期:2021-09-01
随机对照试验数据与类风湿关节炎医保索赔的概率关联:巴瑞替尼临床试验患者的案例研究
Probabilistic linkage of randomized controlled trial data to administrative claims in rheumatoid arthritis: A case study of patients from baricitinib clinical trials
发表日期:2021-06-01
一项在甲氨蝶呤治疗效果不佳的中重度活动性类风湿关节炎患者中对巴瑞替尼与安慰剂进行对比的随机、双盲、安慰剂对照、3期研究的患者报告结果:RA-BALANCE研究结果
Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
发表日期:2021-04-20
巴瑞替尼在中重度特应性皮炎患者中的应用:来自美国和加拿大的随机单药治疗3期试验的结果(BREEZE-AD5)。
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a Randomized Monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)
发表日期:2021-02-16
巴瑞替尼抑制结构性关节损伤影像学进展-临床试验结果综述
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
发表日期:2021-01-04
巴瑞替尼可改善外用皮质类固醇疗效不佳的中重度特应性皮炎患者的症状:两项随机单药治疗Ⅲ期试验的患者报告结果
Baricitinib Improves Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Topical Corticosteroids: Patient-Reported Outcomes from Two Randomised Monotherapy Phase III Trials
发表日期:2020-11-22
巴瑞替尼治疗中重度类风湿关节炎患者3年的疗效:一项长期研究的结果
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
发表日期:2020-11-17
持续性中疾病活动度的类风湿关节炎患者残疾相关因素:一项回顾性队列研究
Factors associated with disability in patients with rheumatoid arthritis with persistent moderate disease activity: a retrospective cohort study
发表日期:2020-10-21
Janus激酶1/2抑制剂巴瑞替尼减少中重度类风湿关节炎中关节破坏的生物标志物
The Janus Kinase 1/2 Inhibitor Baricitinib Reduces Biomarkers of Joint Destruction in Moderate to Severe Rheumatoid Arthritis
发表日期:2020-10-12
在接受巴瑞替尼治疗的类风湿关节炎患者中观察到的与JAK1/JAK2抑制相关的选定血液学参数的变化
Changes in selected haematologic parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
发表日期:2020-10-06
巴瑞替尼联合外用皮质类固醇治疗中重度特应性皮炎的有效性和安全性的随机临床试验
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
发表日期:2020-09-30
巴瑞替尼在中国类风湿关节炎患者中的疗效和安全性及亚组分析:RA-BALANCE研究的结果
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
发表日期:2020-09-02
活动性类风湿关节炎患者在巴瑞替尼临床试验中的感染
Infections in Baricitinib Clinical Trials for Patients with Active Rheumatoid Arthritis
发表日期:2020-08-11
巴瑞替尼在甲氨蝶呤疗效不佳的类风湿关节炎患者中的应用:一项3期研究的结果
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study
发表日期:2020-07-28
类风湿关节炎患者靶向治疗方法的实施和治疗满意度:中国风湿病学家的观点
Implementation of the treat-to-target approach and treatment satisfaction in patients with rheumatoid arthritis: perspectives of Chinese rheumatologists
发表日期:2022-05-17
风湿病专科医师对首个传统合成改善病情抗风湿药治疗失败后类风湿性关节炎患者的治疗偏好启示
Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
发表日期:2021-08-20